YHR214C-E Antibody

What is YHR214C-E and why would researchers develop antibodies against it?

YHR214C-E is a putative uncharacterized protein in Saccharomyces cerevisiae (baker's yeast) with a length of 99 amino acids . Researchers develop antibodies against such proteins to:

• Study protein function and localization within yeast cells

• Investigate protein-protein and protein-RNA interactions

• Examine expression levels under different conditions

• Validate computational predictions about the protein

Methodologically, antibody development against yeast proteins like YHR214C-E typically begins with careful antigen design, often focusing on unique epitopes identified through sequence analysis. While commercial antibodies are rarely available for such uncharacterized proteins, custom antibody development provides essential tools for novel research directions.

What methodologies are most effective for developing monoclonal antibodies against yeast proteins like YHR214C-E?

When developing monoclonal antibodies against yeast proteins like YHR214C-E, researchers should consider these evidence-based approaches:

• Immunogen design and optimization:

  • Utilize recombinant expression of full-length YHR214C-E or synthetic peptides corresponding to predicted epitopes

  • Conjugate smaller peptides to carrier proteins like KLH for improved immunogenicity

  • Consider peptide design based on surface accessibility and hydrophilicity predictions

• Screening strategy:

  • Employ high-throughput screening using parallel ELISAs against both the immunogen and the native protein

  • Screen approximately 1,000+ clones to identify potential candidates, as demonstrated in NeuroMab's approach

  • Test multiple assay conditions simultaneously to identify application-specific antibodies

Recent research demonstrates that hybridoma screening protocols that test approximately 90 positive clones in multiple assay formats (beyond simple ELISA) significantly increase the likelihood of obtaining useful reagents .

How should researchers validate the specificity of YHR214C-E antibodies?

Comprehensive validation of YHR214C-E antibodies requires a multi-assay approach:

• Essential validation experiments:

  • Western blot against yeast lysates with and without the YHR214C-E protein

  • Immunoprecipitation followed by mass spectrometry

  • Immunofluorescence comparing wild-type and knockout strains

  • ELISA testing against recombinant protein

• Gold standard validation approach:

  • Test antibodies in knockout/knockdown models as demonstrated by YCharOS initiative

  • Use CRISPR-Cas9 to generate YHR214C-E knockout yeast strains

  • Compare antibody performance across at least three different techniques (WB, IP, IF)

Research by YCharOS has shown that knockout cell lines provide superior validation compared to other control types, with particular importance for immunofluorescence applications . Their findings revealed that approximately 12 publications per protein target included data from antibodies that failed to recognize the relevant target protein, highlighting the critical importance of thorough validation.

What techniques are most reliable for determining YHR214C-E antibody affinity and specificity?

For rigorous characterization of YHR214C-E antibodies, researchers should employ multiple complementary techniques:

• Affinity measurement:

  • Surface Plasmon Resonance (SPR) to determine KD values

  • Bio-Layer Interferometry (BLI) for real-time binding analysis

  • Isothermal Titration Calorimetry (ITC) for thermodynamic binding parameters

• Specificity assessment:

  • Western blotting against total yeast lysates

  • Competitive binding assays with purified recombinant protein

  • Cross-reactivity testing against related yeast proteins

Recent research on antibody characterization demonstrates KD values in the nanomolar range (7-17 nM) indicate high affinity, as seen with recombinant antibodies against viral targets . Methodological consensus protocols developed by YCharOS and 12 industry partners provide standardized approaches for Western blots, immunoprecipitation, and immunofluorescence that can be applied to YHR214C-E antibody characterization .

How do recombinant antibodies compare to monoclonal antibodies for studying yeast proteins like YHR214C-E?

Comprehensive analysis of recombinant versus monoclonal antibodies reveals important considerations:

YCharOS studies demonstrated that recombinant antibodies outperformed both monoclonal and polyclonal antibodies across multiple assay types . For YHR214C-E research, recombinant antibodies offer significant advantages, particularly for reproducibility in long-term studies.

What protein characterization techniques should be paired with YHR214C-E antibody detection for comprehensive protein analysis?

For robust YHR214C-E characterization, researchers should combine antibody-based detection with complementary protein analysis techniques:

• Orthogonal techniques to complement antibody-based detection:

  • Mass spectrometry for unbiased protein identification and PTM analysis

  • RNA analysis (RT-qPCR) to correlate transcript and protein levels

  • Protein-protein interaction mapping (yeast two-hybrid or proximity labeling)

  • Computational prediction of protein function and structure

• Integrated analysis approach:

  • Combine antibody-based localization with functional assays

  • Correlate antibody-detected expression with phenotypic outcomes

  • Validate protein-RNA interactions predicted by computational tools like catRAPID

The RNAct database shows numerous predicted RNA interactions for YHR214C-E , which could be experimentally validated using antibodies in RNA immunoprecipitation assays followed by sequencing (RIP-seq) or similar techniques.

How can high-throughput approaches be used to characterize antibodies against yeast proteins like YHR214C-E?

For efficient, large-scale characterization of antibodies against targets like YHR214C-E:

• High-throughput screening methodologies:

  • Microarray-based epitope mapping

  • Automated Western blot platforms

  • High-content imaging for localization studies

  • Multiplexed binding assays

• Implementation strategy:

  • Develop standardized protocols across assays

  • Use consensus protocols established by collaborative efforts like YCharOS

  • Employ CE-SDS (capillary electrophoresis-sodium dodecyl sulfate) for antibody quality assessment

Research comparing CE-SDS platforms for monoclonal antibody characterization demonstrates the importance of assessing linearity, sensitivity, precision, reproducibility, and resolution for high-throughput applications .

What machine learning approaches can enhance the development and characterization of antibodies against targets like YHR214C-E?

Advanced computational methods can significantly improve antibody research:

• Active learning strategies:

  • Library-on-library approaches for many-to-many antibody-antigen relationships

  • Iterative expansion of labeled datasets from small initial subsets

  • Out-of-distribution prediction models for novel antibody-antigen interactions

• Practical implementation:

  • Begin with a well-characterized training set of similar yeast protein antibodies

  • Implement active learning algorithms that have demonstrated 35% reduction in required antigen mutant variants

  • Use computational models to accelerate learning processes by approximately 28 steps compared to random baseline approaches

Recent research using the Absolut! simulation framework evaluated fourteen novel active learning strategies and identified three algorithms that significantly outperformed baseline approaches for antibody-antigen binding prediction .

How can researchers effectively use YHR214C-E antibodies to study protein-RNA interactions?

Given the predicted RNA interactions of YHR214C-E shown in the RNAct database , researchers can employ several methodological approaches:

• RNA immunoprecipitation techniques:

  • Standard RIP using YHR214C-E antibodies followed by RT-qPCR or sequencing

  • CLIP (Cross-Linking and Immunoprecipitation) for direct RNA-protein interaction sites

  • PAR-CLIP or iCLIP for enhanced resolution of binding sites

• Validation approaches:

  • Compare experimental results with prediction scores from computational tools

  • Use z-scores (as shown in RNAct database) to prioritize validation targets

  • Correlate RNA binding with functional outcomes through phenotypic assays

The RNAct database shows consistent negative z-scores (-2) for YHR214C-E interactions with various RNAs , which would require careful experimental validation using well-characterized antibodies.

What are the most common pitfalls in YHR214C-E antibody experiments and how can they be addressed?

When working with antibodies against uncharacterized yeast proteins like YHR214C-E, researchers should be aware of these common issues:

• Common experimental challenges:

  • Non-specific binding in complex yeast lysates

  • Poor antibody performance across different applications

  • Insufficient validation leading to misleading results

  • Batch-to-batch variability affecting reproducibility

• Solutions and preventative measures:

  • Implement YCharOS-recommended validation protocols using knockout controls

  • Test each antibody batch in all intended applications before experimental use

  • Include appropriate positive and negative controls in all experiments

  • Document all validation experiments thoroughly for publication

Research has shown that ~50% of commercial antibodies fail to meet basic standards for characterization, resulting in estimated financial losses of $0.4–1.8 billion per year in the United States alone .

How should researchers reconcile contradictory results when using different antibodies against YHR214C-E?

When facing conflicting data from different antibodies targeting the same protein:

• Systematic reconciliation approach:

  • Compare epitope specificity between antibodies

  • Evaluate validation methods used for each antibody

  • Test antibodies side-by-side under identical conditions

  • Consider protein conformation, modifications, and interaction partners

• Resolution strategy:

  • Prioritize results from antibodies validated with knockout controls

  • Use orthogonal, non-antibody-based methods to resolve conflicts

  • Consider combinations of antibodies targeting different epitopes

  • Report all conflicting results transparently in publications

Recent research demonstrated that an average of ~12 publications per protein target included data from antibodies that failed to recognize the relevant target protein , highlighting how common conflicting results can be when using inadequately characterized antibodies.

What quality control standards should be applied to YHR214C-E antibodies throughout a research project?

For maintaining antibody quality throughout a research project:

• Ongoing quality control measures:

  • Regular testing against positive and negative controls

  • Monitoring for changes in performance over time and storage conditions

  • Batch testing before use in critical experiments

  • Documentation of all quality control results

• Documentation standards:

  • Record complete antibody details (including catalog numbers, lot numbers, and RRID identifiers)

  • Document all validation experiments including images and quantification

  • Maintain detailed protocols for each application

  • Create standardized quality control checkpoints at defined intervals

The Research Resource Identifier (RRID) program plays a crucial role in antibody tracking and reproducibility efforts , and should be implemented for all antibodies, including those targeting YHR214C-E.

How might proteomically validated YHR214C-E antibodies contribute to yeast systems biology?

Well-characterized antibodies against YHR214C-E could advance yeast research in several ways:

• Systems biology applications:

  • Integration of protein localization data into yeast interactome maps

  • Correlation of protein expression with phenotypic outcomes under various conditions

  • Validation of computational models of protein function

  • Examination of protein behavior during stress responses

• Methodological approach:

  • Combine antibody-based detection with multi-omics datasets

  • Use antibodies to validate predicted protein-protein interactions

  • Employ quantitative immunoblotting to measure expression changes across conditions

  • Apply antibodies in ChIP-seq or similar techniques if YHR214C-E has DNA/chromatin associations

The development of proteome-wide approaches targeting the human proteome has demonstrated valuable lessons that can be applied to model organisms like yeast .

What emerging technologies could improve YHR214C-E antibody development and characterization?

Several cutting-edge approaches show promise for enhancing antibody research:

• Emerging antibody technologies:

  • Single B-cell cloning for rapid monoclonal antibody development

  • Phage display libraries for antibody selection without animal immunization

  • CRISPR-engineered cell lines for improved validation

  • Advanced computational tools for epitope prediction and antibody engineering

• Implementation considerations:

  • Balance technology adoption with established validation principles

  • Incorporate new technologies within standardized characterization frameworks

  • Validate novel approaches against gold standard methods

  • Consider cost-benefit analysis for emerging technologies

Recent developments in renewable antibody technology and KO cell line validation, as demonstrated by initiatives like YCharOS , represent significant advances that could be applied to yeast protein antibody development.

How can researchers contribute to community standards for yeast protein antibodies like YHR214C-E?

To advance the field collectively:

• Community contribution opportunities:

  • Share detailed validation data in public repositories

  • Participate in collaborative characterization efforts

  • Adopt standardized reporting formats for antibody experiments

  • Contribute to consensus protocols for yeast protein antibody validation

• Practical implementation:

  • Follow reporting guidelines similar to those developed by YCharOS and industry partners

  • Submit antibody characterization data to repositories similar to Antibodypedia

  • Report both positive and negative results to build collective knowledge

  • Cite antibodies using RRIDs to enable tracking across publications